SEOUL Jan 17 Samsung Bioepis Co Ltd said on Sunday it had received European Commission approval for its copy of the blockbuster biotech arthritis drug Enbrel.
The drug, known scientifically as etanercept, will be sold in Europe by U.S. biotechnology group Biogen and rolled out gradually across all 28 European Union member states as well as Norway, Iceland and Liechtenstein, the South Korean company said in a statement.
05:17 South Korea Prosecutor To Seek Arrest Warrant For Samsung Group Chief Jay Y. Lee19
06:50 South Korean prosecutors seek warrant to arrest Samsung head for bribery14
23:07 South Korea investigators mull arrest warrant for Samsung leader: Yonhap20
02:01 Samsung Group chief summoned as 'suspect' in corruption scandal19